RIGL News and Press, Rigel Pharmaceuticals Inc. From 03/04/25

2025-03-04 16:03:27 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents Rigel Pharmaceuticals sets 2025 sales outlook above estimates Seeking Alpha’s Quant Rating on Rigel Pharmaceuticals Histor...

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update PR Newswire Fourth quarter 2024 total revenue of approximately $57.6 million , which includes TAVALISSE ® net product sales of $31.0 million , REZLIDHIA ® ...

Veritec, Inc. (VRTC) is expected to report for quarter end 2024-12-31 Nayax Ltd. (NYAX) is expected to report $0.04 for Q4 2024 CrowdStrike Holdings Inc. (CRWD) is expected to report $0.01 for Q4 2025 Schaeffler AG Bearer Preference Shares (SCFLF) is expected to report for quarter end...

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced t...

2025-02-21 22:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease PR Newswire First patient enrolled in NIH/NHLBI-sponsored Phase 1 Study of fostamatinib, Rigel's oral SYK inhibitor SOUTH SAN FRANCISCO, Calif. , Jan. 22, ...

2025-01-20 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-01-13 12:49:19 ET Read the full article on Seeking Alpha For further details see: Rigel Pharmaceuticals sets 2025 sales outlook above estimates

Rigel Provides Business Update and 2025 Outlook PR Newswire Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE ® net product sales of $31.0 million , REZLIDHIA ® net product sales of $7.4 million ...

2025-01-09 08:25:45 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript Rigel Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Present...